Karishma G. Gopaul

FDA investigator

Appears on 8 documents from 2022 to 2026, most often at sites in New York. Most often cites control of microbiological contamination (21 CFR 211.113).

8
Documents on file
4.3
Observations per 483
2022
First seen
2026
Most recent

What they cite most

From 34 observations

Activity by year

2022: 1, 2023: 3, 2024: 1, 2025: 1, 2026: 2

Where

New York 3 · India 2 · New Jersey 1 · North Carolina 1 · Pennsylvania 1

Is Karishma G. Gopaul coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

8 documents, newest first
FirmOpen
483 Cipla LimitedApr 17, 2026 · Salcette, India
483 Fresenius Kabi USA, LLCFeb 13, 2026 · Wilson, North Carolina
483 Granules India LimitedJun 20, 2025 · Sangareddy, India
483 ProRx LLCAug 2, 2024 · Exton, Pennsylvania
483 Sciarra Laboratories, IncAug 7, 2023 · Hicksville, New York
483 Maimonides Medical Center - PharmacyMar 9, 2023 · Brooklyn, New York
483 Novel Laboratories, Inc.Jan 13, 2023 · Somerset, New Jersey

About this profile

What does Karishma G. Gopaul inspect?

Karishma G. Gopaul appears on 8 documents on file covering 8 sites, most often in New York.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.22 and 21 CFR 211.160.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Karishma G. Gopaul is dated Apr 17, 2026.